NervGen Pharma Corp. (TSXV:NGEN)

Market Cap	262.21M
Revenue (ttm)	n/a
Net Income (ttm)	-25.61M
Shares Out	72.84M
EPS (ttm)	-0.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,694
Average Volume	78,656
Open	3.690
Previous Close	3.600
Day's Range	3.570 - 3.830
52-Week Range	2.050 - 7.050
Beta	0.52
RSI	45.52
Earnings Date	Aug 14, 2025

About NervGen Pharma

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer’s disease; and NVG-300, which is in a preclinical model of ischemic stroke and confirmatory SCI study. NervGen Pharma Corp. has a licensing agreement wi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 7
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: NGEN